Antimicrobials · Cephalosporins
The facts most likely to be tested
Press 1–5 to rate · ↑↓ to navigate
Ceftaroline is a fifth-generation cephalosporin with activity against methicillin-resistant Staphylococcus aureus (MRSA).
The mechanism of action involves high-affinity binding to penicillin-binding protein 2a (PBP2a), which is the altered target site responsible for methicillin resistance.
Ceftaroline provides broad-spectrum coverage including Gram-positive organisms and common Gram-negative pathogens, but it lacks activity against Pseudomonas aeruginosa.
Clinical indications for ceftaroline include community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI).
Ceftaroline is structurally similar to other cephalosporins and is generally considered safe for patients with penicillin allergies who do not have a history of anaphylaxis or IgE-mediated reactions.
The drug is administered via intravenous infusion and requires renal dose adjustment in patients with moderate to severe renal impairment.
Ceftaroline is often utilized as a salvage therapy or alternative for complicated infections where vancomycin is ineffective or contraindicated.
Vignette unlocked
A 58-year-old male with a history of type 2 diabetes is hospitalized for a non-healing foot ulcer that has progressed to cellulitis. Physical examination reveals erythema, warmth, and purulent drainage extending to the mid-calf. He has a documented history of vancomycin-induced red man syndrome and persistent nephrotoxicity during previous admissions. Blood cultures are pending, but local surveillance indicates a high prevalence of MRSA. The patient is hemodynamically stable with a creatinine clearance of 45 mL/min.
Which of the following is the most appropriate antibiotic choice to cover the suspected pathogen while avoiding the patient's previous adverse reactions?
Ceftaroline
Ceftaroline is the appropriate choice because it provides coverage against MRSA via PBP2a binding and avoids the nephrotoxicity and red man syndrome associated with vancomycin.
Full handout
High yield triage
Classification
5th generation cephalosporin; the only beta-lactam with activity against MRSA.
Indications
MRSA skin/soft tissue infections and community-acquired pneumonia.
Mechanism of Action
Binds to PBP2a to inhibit cell wall synthesis in resistant organisms.
Side Effects
Diarrhea, nausea, and C. difficile colitis.
Contraindications / Monitoring
Anaphylaxis to beta-lactams. Monitor renal function (CrCl).
Full handout
Mechanism of Action
Ceftaroline binds with high affinity to PBP2a, a modified penicillin-binding protein found in methicillin-resistant Staphylococcus aureus. By inhibiting peptidoglycan cross-linking, it effectively disrupts the bacterial cell wall. Unlike other cephalosporins, this unique binding allows it to overcome the resistance mechanism that renders other beta-lactams ineffective against MRSA.
Unique Properties
It is the only cephalosporin with clinical activity against MRSA and Streptococcus pneumoniae resistant to penicillin. It maintains the broad gram-negative coverage typical of later-generation cephalosporins while providing essential gram-positive coverage.
Indications
Indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates. Also approved for community-acquired bacterial pneumonia (CABP) where coverage for resistant organisms is required.
Pharmacokinetics
Administered via intravenous infusion. It is primarily excreted via the kidneys; therefore, dosage adjustments are mandatory in patients with renal impairment (CrCl < 50 mL/min).
Side Effects & Adverse Events
Common adverse effects include diarrhea, nausea, and rash. Patients are at risk for C. difficile-associated diarrhea due to broad-spectrum activity. Rare but serious hypersensitivity reactions including anaphylaxis may occur.
Contraindications
Absolute contraindication in patients with a history of severe anaphylaxis to any cephalosporin or beta-lactam antibiotic. Use with extreme caution in patients with a history of penicillin allergy due to potential cross-reactivity.
Monitoring
Monitor renal function (serum creatinine and CrCl) to guide dose adjustments. Observe for signs of superinfection, specifically persistent diarrhea suggestive of C. difficile.
Clinical Pearls
Think of Ceftaroline as the 'anti-MRSA' cephalosporin. It is a frequent board answer for patients with MRSA pneumonia or skin infections who cannot tolerate or have failed vancomycin therapy.